Brief: Lipella Pharmaceuticals Successfully Completes Phase 2A Clinical Trial Announces Late-Breaking Presentation At The Annual Meeting Of The American Urological Association
16/03/2023 12:35
March 16 (Reuters) - Lipella Pharmaceuticals Inc LIPO.O :
* LIPELLA PHARMACEUTICALS SUCCESSFULLY COMPLETES PHASE 2A
CLINICAL
TRIAL; ANNOUNCES LATE-BREAKING PRESENTATION AT THE ANNUAL
MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION
* LIPELLA PHARMACEUTICALS - ALL SUBJECTS TOLERATED LP-10
INSTILLATIONS AND COMPLETED STUDY WITHOUT REPORT OF PRODUCT
RELATED SERIOUS ADVERSE EVENTS
* LIPELLA PHARMACEUTICALS INC - LP-10 PHARMACOKINETIC
ANALYSIS
DEMONSTRATED VERY SHORT DURATION OF SYSTEMIC UPTAKE
Source text for Eikon: ID:nPnblRYrXa
Further company coverage: LIPO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Lipella Pharmaceuticals
See all newsBrief: Lipella Pharmaceuticals Says Bankruptcy Court Approves Sale And Asset Purchase Agreement On June 4
Brief: Lipella Pharmaceuticals Inc. Files Voluntary Petitions For Relief Under Chapter 11
Brief: Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study Of LP-10 In Oral Lichen Planus
Brief: Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group